FDA reviewing Teva's Huntington's drug; Vertex hands back $3M in tax break;

@FierceBiotech: We're looking for 2015's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: What does Google's corporate shuffle mean for its biotech ambitions? Story | Follow @JohnCFierce

@DamianFierce: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Warning letter | Follow @DamianFierce

> Teva ($TEVA) says that the FDA has accepted the NDA for its Huntington's drug dubbed SD-809 (deutetrabenazine). Release

> Vertex ($VRTX) worked out a deal with the City of Boston to trim its tax break by $3 million a year after failing to come through with all the new jobs it promised ahead of building a new headquarters in the Seaport District. Story

> The CRO Accelovance is adding 70 jobs in Wales. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Rehabilitation startup rolls out new muscle therapy device for leg paralysis. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Device industry suffers from first-mover disadvantage due to FDA regs. Article | Follow @VarunSaxena2

@EmilyWFierce: UPDATED: Kim Kardashian Instagram post lands Duchesnay in FDA hot water. More from FiercePharmaManufacturing | Follow @EmilyWFierce

> New York startup trots out video-game like screening device for Alzheimer's. Story

> Helius enters clinical trial of its PoNS brain stimulation device to treat traumatic brain injury. More

> Wearable pain relief device set to hit store shelves due to distribution alliance. Report

Pharma News

@FiercePharma: Real-time data can put slow drug launches into the fast lane, researcher says. More from FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: GSK stops production at North Carolina plant after Legionella bacteria found in cooling tower. News | Follow @EricPFierce

@CarlyHFierce: Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. FiercePharmaMarketing story | Follow @CarlyHFierce

> GSK site closed after Legionella bacteria detected in cooling tower. More

> Roche scores Accutane victory with reversal of $25M verdict. Story

> Daiichi clot-buster wins a NICE green light, but still faces an uphill track. Article

Biotech Research News

> Vitamin B3 pathway may lead to new obesity drugs. Item

> MGH study pinpoints a genetic trigger for heart valve disorder. Report

> UBC team stakes a claim on a newly discovered 'obesity gene.' More

> Overstimulating oncogene family SRC shows promise against cancer. Story

> TSRI researchers say enzyme may work as an anti-smoking treatment. Article

Diagnostics News

> VisionGate sets sights on FDA approval for noninvasive lung cancer Dx. Editor's corner

> Biocept partners with UC Irvine on liquid biopsy research. News

> Response Genetics throws in towel, sells out to Cancer Genetics for $14M. More

> Roche selects Hawaii's Diagnostic Laboratory Services for molecular diagnostics project. Report

> Invitae dials up testing guidance amid positive Q2 numbers. Article

Pharma Marketing News

> Legionnaires' discovery prompts GlaxoSmithKline to idle NC plant. Item

> Real-time data can put slow drug launches into the fast lane, researcher says. Report

> Abbott, Novartis tap into #ILookLikeAnEngineer social media movement. More

> Kim Kardashian Instagram post lands Duchesnay in FDA hot water. Story

> Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. Article

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.